Second generation drug-eluting stents: A review of the everolimus-eluting platform

Clinical Medicine Insights: Cardiology

Volumn 7, Issue , 2013, Pages 115-126

  Whitbeck, Matthew G ^a   Applegate, Robert J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Drug eluting stents; Everolimus

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; TISSUE SCAFFOLD;

BARE METAL STENT; CLINICAL EFFECTIVENESS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ELUTING STENT; HUMAN; IN-STENT RESTENOSIS; NEOINTIMA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; REVIEW; STENT THROMBOSIS;

EID: 84880822308     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S11516     Document Type: Review

References (34)

1. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxelcoated coronary stents for the treatment of patients with de novo coronary lesions: Angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109:1948-1954. Published online before print April 12, 2004, doi: 10.1161/01.CIR.0000127129.94129.6F
2. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): A first-in-human multicenter pilot trial. Catheter Cardiovasc Interv. 2003;60(2):172-178.
3. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009-1019.
4. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584-9251.
5. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet. 2007;369:667-678.
6. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773-1780.
7. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
8. Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of de novo coronary disease using a single paclitaxel-eluting stent). J Am Coll Cardiol Intv. 2009;2(12):1248-1259.
9. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circ. 2001;103:2816-2821.
10. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO-2) Trial. J Am Coll Cardiol. 2003;41(8):1283-1288.
11. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756-758.
12. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52(5):333-342.
13. Wiemer M, Serruys PW, Miguel-Hebert K, et al. Five-year long-term clinical follow-up of the XIENCE V everloimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial. Catheter Cardiovasc Interv. 2010;75(7): 997-1003.
14. Garg S, Serruys P, Onuma Y, et al. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009;2(12):1190-1198.
15. Stone GW, Midei M, Newman W, et al. Comparison of an everolimuseluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA. 2008;299(16):1903-1913.
16. Caixeta A, Lansky AJ, Serruys PW, et al. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: A pooled analysis from the SPIRIT II (a clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions) and SPIRIT III (a clinical evaluation of the investigational device XIENCE V everolimus eluting coronary stent system [EECSS] in the treatment of subjects with de novo native coronary artery lesions) randomized trials. JACC Cardiovasc Interv. 2010;3(12):1220-1228.
17. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18): 1663-1674.
18. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (a prospective, randomized, multicenter trial to assess an everolimuseluting coronary stent system [PROMUS Element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57(16):1700-1708.
19. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimuseluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet. 2010;375(9710):201-209.
20. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: The intracoronary stenting and agiographic results: Test efficacy of 3 limus-eluting stents (ISAR-TEST-4) trial. Eur Heart J. 2009;30(20):2441-2449.
21. Sarno G, Lagerqvist B, Carlsson J, et al. Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Int J Cardiol. 2012; Epub ahead of print.
22. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136-146.
23. Silber S, Windecker S, Vranckx P, Serruys PW, RESOLUTE All Comers Investigators. Unrestricted randomised use of two new generation drugeluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011;377(9773): 1241-1247.
24. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961-972.
25. Onuma Y, Serruys PW, Kukreja N, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents: Pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. Eur Heart J. 2010;31(9): 1071-1078.
26. Riley RF, Don CW, Powell W, Maynard C, Dean LS. Trends in coronary revascularization in the United States from 2001 to 2009: Recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes. 2011;4(2):193-197.
27. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-8. JAMA. 2011;305(17): 1769-1776.
28. Mitka M. Researchers praise drug-eluting stents but appropriate use is still debated. JAMA. 2011;305(20):2052-2053.
29. Park SJ, Kim YH. Current status of percutaneous coronary intervention with drug-eluting stents in Asia. Circulation. 2008;118(25):2730-2737.
30. JP Morgan Interventional Cardiology. JP Morgan. Feb 2, 2012.
31. Industry Estimate. Industry Estimate. 2013.
32. Amin AP, Reynolds MR, Lei Y, et al. Cost-effectiveness of everolimusversus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial). Am J Cardiol. 2012;110(6):765-770.
33. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimuseluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897-910.
34. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58(15):1578-1588.